Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)
Kathryn Lurain(The Ohio State University), Robert Yarchoan(National Cancer Institute), Denise Whitby(Frederick National Laboratory for Cancer Research), Ralph Mangusan(AIDS United), Thomas S. Uldrick(Regeneron (United States)), Vickie Marshall(Leidos (United States)), Maryalice Stetler‐Stevenson(National Cancer Institute), Anaida Widell(AIDS United), Ramya Ramaswami(National Cancer Institute), Irene Ekwede(AIDS United), Elaine S. Jaffe(National Cancer Institute), Hao‐Wei Wang(Fu Jen Catholic University), Mark J. Roth(National Cancer Institute), Stefania Pittaluga(New York University), Jomy George(National Institutes of Health), Constance M. Yuan(National Cancer Institute)
Cited by 5
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
|Blood|2011|2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k